JW Pharmaceutical (XKRX:001060) Other Net Income (Loss) : ₩-0 Mil (TTM As of Mar. 2024)

View and export this data going back to 1976. Start your Free Trial

What is JW Pharmaceutical Other Net Income (Loss)?

JW Pharmaceutical's Other Net Income (Loss) for the three months ended in Mar. 2024 was ₩0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-0 Mil.

JW Pharmaceutical's annual Other Net Income (Loss) increased from Dec. 2021 (₩-0 Mil) to Dec. 2022 (₩0 Mil) and increased from Dec. 2022 (₩0 Mil) to Dec. 2023 (₩0 Mil).

JW Pharmaceutical Other Net Income (Loss) Historical Data

The historical data trend for JW Pharmaceutical's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW Pharmaceutical Other Net Income (Loss) Chart

JW Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

JW Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

JW Pharmaceutical Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-0 Mil.

JW Pharmaceutical Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of JW Pharmaceutical's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

JW Pharmaceutical (XKRX:001060) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JW Pharmaceutical (XKRX:001060) » Definitions » Other Net Income (Loss)

Traded in Other Exchanges

001067:Korea 001065.PFD:Korea

Address

2477, Nambusunhwan-ro, Seocho-gu, KOR

Website

https://www.jw-pharma.co.kr

JW Pharmaceutical is active in the healthcare sector. It has been one of the leading companies in the pharmaceutical market on a global basis. Its original medicine and medical supply pipeline include Livalo, Thrupas, Sigmart and Actemra. It also develops low-protein and low-salt diet food for patients suffering from chronic renal insufficiency as well as general Pharmaceuticals and health care products.

JW Pharmaceutical (XKRX:001060) Headlines

No Headlines